GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
GO:0031396111 | Esophagus | ESCC | regulation of protein ubiquitination | 154/8552 | 210/18723 | 2.70e-16 | 2.04e-14 | 154 |
GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
GO:0019079111 | Esophagus | ESCC | viral genome replication | 102/8552 | 131/18723 | 4.31e-14 | 2.19e-12 | 102 |
GO:0050792111 | Esophagus | ESCC | regulation of viral process | 119/8552 | 164/18723 | 2.19e-12 | 9.03e-11 | 119 |
GO:007189716 | Esophagus | ESCC | DNA biosynthetic process | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
GO:1903900111 | Esophagus | ESCC | regulation of viral life cycle | 106/8552 | 148/18723 | 1.26e-10 | 3.72e-09 | 106 |
GO:0045069110 | Esophagus | ESCC | regulation of viral genome replication | 67/8552 | 85/18723 | 3.81e-10 | 1.04e-08 | 67 |
GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
GO:0031397111 | Esophagus | ESCC | negative regulation of protein ubiquitination | 63/8552 | 83/18723 | 1.87e-08 | 3.65e-07 | 63 |
GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
GO:1903321111 | Esophagus | ESCC | negative regulation of protein modification by small protein conjugation or removal | 69/8552 | 95/18723 | 8.54e-08 | 1.44e-06 | 69 |
GO:004852516 | Esophagus | ESCC | negative regulation of viral process | 66/8552 | 92/18723 | 3.49e-07 | 4.88e-06 | 66 |
GO:004507114 | Esophagus | ESCC | negative regulation of viral genome replication | 44/8552 | 56/18723 | 4.84e-07 | 6.50e-06 | 44 |
GO:007053413 | Esophagus | ESCC | protein K63-linked ubiquitination | 44/8552 | 56/18723 | 4.84e-07 | 6.50e-06 | 44 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP10 | SNV | Missense_Mutation | novel | c.1092G>A | p.Met364Ile | p.M364I | | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP10 | SNV | Missense_Mutation | novel | c.2207G>T | p.Arg736Leu | p.R736L | | protein_coding | tolerated(0.08) | benign(0.072) | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PARP10 | SNV | Missense_Mutation | novel | c.1847N>C | p.Gly616Ala | p.G616A | | protein_coding | tolerated(0.12) | benign(0.042) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP10 | SNV | Missense_Mutation | novel | c.2947N>A | p.Val983Met | p.V983M | | protein_coding | tolerated(0.24) | benign(0.285) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PARP10 | SNV | Missense_Mutation | rs782279171 | c.2075N>A | p.Arg692Gln | p.R692Q | | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PARP10 | SNV | Missense_Mutation | rs782036506 | c.626N>A | p.Arg209His | p.R209H | | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PARP10 | SNV | Missense_Mutation | novel | c.2667N>T | p.Glu889Asp | p.E889D | | protein_coding | tolerated(0.42) | benign(0) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
PARP10 | SNV | Missense_Mutation | rs782213808 | c.2665N>C | p.Glu889Gln | p.E889Q | | protein_coding | tolerated(0.46) | benign(0.011) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
PARP10 | SNV | Missense_Mutation | | c.3068N>T | p.Ser1023Phe | p.S1023F | | protein_coding | deleterious(0.04) | benign(0.316) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PARP10 | SNV | Missense_Mutation | novel | c.487N>A | p.Glu163Lys | p.E163K | | protein_coding | tolerated(0.5) | benign(0.007) | TCGA-VS-A952-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |